Compare MXCT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | ENTX |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 147.4M |
| IPO Year | 2021 | 2015 |
| Metric | MXCT | ENTX |
|---|---|---|
| Price | $1.38 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.11 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 1.4M | 228.1K |
| Earning Date | 11-10-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.33 |
| Revenue | ★ $33,026,000.00 | $42,000.00 |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | ★ N/A | $9.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $0.91 |
| 52 Week High | $1.80 | $4.20 |
| Indicator | MXCT | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 57.67 |
| Support Level | $1.02 | $2.71 |
| Resistance Level | $1.54 | $3.26 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 70.41 | 56.15 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.